16th July 2022 | Pharma Updates

PharmaState Updates – Latest Pharma Happenings

Indian pharma MSMEs have a variety of opportunities in foreign markets: Pharmexcil

Indian MSME business owners have numerous options to sell their goods in global markets. As per director of the council, they must sign up for membership in the Pharmaceutical Export Promotion Council if they intend to export.

Sanofi reports phase 3 Dupixenttrial in children aged 1 to 11 with eosinophilic esophagitis

The primary goal of a phase 3 trial evaluating the experimental use of Dupixent (dupilumab) in children aged 1 to 11 years with eosinophilic esophagitis was achieved at 16 weeks with both higher and lower dose weight-tiered regimens.

Pharma exports increased by 8% in the first quarter while imports fell by 23%

While imports decreased by 22.78% over the same period, exports of medications and pharmaceuticals increased by 8.05% during the first three months of the fiscal year 2022–23.

China's wager on Big Pharma may alter the IP landscape

Big Pharma has already made large investments in emerging markets like China and India, notably in outsourcing; but, given their formidable obstacles, it is important to consider how successful they will be in the long run.

Pfizer's Xalkori receives FDA approval for treating uncommon ALK-positive tumors

For the fourth time in 11 years, the FDA has approved Pfizer’s Xalkori to treat cancer that has an ALK mutation. The permission is for patients whose cancers are progressing despite past treatment and cannot be removed surgically.

GenScript ProBio & DAAN Bio Therapeutics announce partnership for cell & gene therapy

A strategic collaboration MOU has been signed between GenScript ProBio and DAAN Bio Therapeutics, a brand-new pharmaceutical company that specializes in developing cell therapy and antibody medicines.

US FDA deferred action on BeiGene's BLA for tislelizumab in 2L ESCC

FDA has postponed making a decision on the Biologics License Application (BLA) for tislelizumab as a second-line (2L) treatment for patients with unresectable or metastatic esophageal squamous cell carcinoma.